Wave Life Sciences reveals WVE-007 obesity trial startup in Q1 2025, new RNA editing programs

Wave Life Sciences Ltd.

WVE-007 (INHBE GalNAc-siRNA) on track for Phase 1 in Q1 2025; preclinical data show monotherapy, add-on to GLP-1s, and maintenance potential.
Three new wholly owned GalNAc-RNA editing programs: PNPLA3, LDLR, APOB targeting cardiometabolic diseases; candidate selection expected in 2025.
Wave aims to have five GalNAc-siRNA or RNA editing programs in the clinic by 2026.
Proprietary chemistry innovations (PN backbone, N3U) enhance intracellular delivery and RNA editing efficiency.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.